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Abstract
Background Steroid-resistant nephrotic syndrome (SRNS), commonly caused by focal segmental glomerulosclerosis (FSGS), 
is associated with progression to stage 5 chronic kidney disease, requirement for kidney replacement therapy and a risk of 
disease recurrence post-kidney transplantation. Ofatumumab (OFA) is a fully humanised monoclonal antibody to CD20, 
with similar mechanisms of action to rituximab (RTX).
Methods We report a case series of seven UK patients (five paediatric, two adult), all of whom developed FSGS recurrence 
after kidney transplantation and received OFA as part of their therapeutic intervention. All also received concomitant plasma-
pheresis. The 2-year outcome of these seven patients is reported, describing clinical course, kidney function and proteinuria.
Results Four patients (all paediatric) achieved complete urinary remission with minimal proteinuria 12 months post-treat-
ment. Three of those four also had normal graft function. Two patients showed partial remission—brief improvement to 
non-nephrotic proteinuria (197 mg/mmol) in one patient, maintained improvement in kidney function (estimated glomerular 
filtration rate 76 ml/min/1.73  m2) in the other. One patient did not demonstrate any response.
Conclusions OFA may represent a useful addition to therapeutic options in the management of FSGS recurrence post-trans-
plantation, including where RTX has shown no benefit. Concomitant plasmapheresis in all patients prevents any definitive 
conclusion that OFA was the beneficial intervention.
Keywords Transplant outcomes · Steroid-resistant nephrotic syndrome · Immunosuppression · Plasmapheresis
Introduction
Steroid-resistant nephrotic syndrome (SRNS) is defined as 
proteinuria > 200 mg/mmol creatinine, hypoalbuminaemia 
and clinical oedema with no remission of proteinuria fol-
lowing 4 weeks of high-dose (2 mg/kg) corticosteroids, 
or subsequent loss of steroid responsiveness over time. In 
childhood, focal segmental glomerulosclerosis (FSGS) is the 
most common histological finding in SRNS. Progression to 
stage 5 chronic kidney disease (CKD 5) and requirement for 
kidney replacement therapy is common in FSGS—43–94% 
of patients enter CKD 5 within 10  years of diagnosis, 
depending on immunosuppressant response [1].
Various immunosuppressive agents trialled in FSGS 
include calcineurin inhibitors (ciclosporin, tacrolimus), 
mycophenolate mofetil and the chimeric anti-CD20 mon-
oclonal antibody, rituximab (RTX); calcineurin inhibi-
tion is recommended as first-line treatment in pre-dial-
ysis patients. FSGS carries a risk of disease recurrence 
post-kidney transplant. The risk of disease recurrence is 
increased in patients presenting at a younger age, with 
initial steroid sensitivity, or no identified genetic muta-
tions—all felt to represent an immunological aetiology 
being more likely, and no response to other trialled immu-
nosuppressive therapies [2, 3], and much lower where a 
secondary cause is identified. Confirmation of a genetic 
aetiology or complete steroid resistance does not pre-
clude recurrence. Recurrence may occur within hours of 
transplantation or months to years later. Management of 
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FSGS recurrence post-transplant is not standardised, with 
no robust evidence to support any particular management 
stratagem in all patients—likely partly attributable to the 
disease heterogeneity itself [4]. Current accepted strate-
gies include the use of plasmapheresis (PLEX), optimisa-
tion of calcineurin inhibitors and depletion of B cells using 
a monoclonal antibody, most commonly RTX [5]. Many 
hypotheses presume an as-yet unidentified circulating fac-
tor [2], hence the rationale for PLEX in disease recurrence 
post-transplant, which has a reasonable body of literature 
to support its use [6]. PLEX is reportedly more effective in 
early recurrence and in paediatric patients [7, 8].
Recommendations on dose and duration of PLEX are 
weaker, although current international guidance suggests 
three daily exchanges then six further exchanges over 
2 weeks, or a slow weaning course over 9 months [6]. More 
intensive PLEX regimens have been used with some success 
[9, 10]. Additional immunosuppression is recommended, as 
PLEX serves only to remove the presumptive circulating 
‘permeability factor’. Limited evidence exists surround-
ing the use of ciclosporin, cyclophosphamide, intravenous 
immunoglobulin, and more esoteric therapies such as galac-
tose and bone marrow mesenchymal stem cell infusions 
[11–13].
With the assumption that the circulating factor is B-cell 
derived/influenced, RTX has been used to treat post-trans-
plant recurrence, with some success [14]. RTX is a chimeric 
humanised murine monoclonal antibody directed against the 
large extracellular loop of CD20, commonly expressed on 
B cells, and used for B-cell depletion (although ineffective 
against pre-B cells and fully differentiated plasma cells, nei-
ther of which express CD20). Usage of RTX includes proven 
benefit in steroid-sensitive nephrotic syndrome and some 
limited benefit in SRNS with a reported 20–44% response 
rate [15]. RTX was first used in a patient with post-transplant 
FSGS recurrence as part of chemotherapy for post-transplant 
lymphoproliferative disease with the unexpected benefit of 
disease remission [16]. Subsequently, RTX has been used 
peri-operatively at the time of transplant [17] and in manage-
ment of recurrent FSGS [18] with some success. Response 
to RTX appears more likely in paediatric patients [18]—
whether this represents a different aetiology in paediatric 
FSGS or intrinsic differences in younger patients’ response 
is unknown.
Ofatumumab (OFA) is a fully humanised monoclonal 
antibody directed against CD20, binding both the small and 
large extracellular loop [19]. Being fully humanised reduces 
the likelihood of reaction to the murine elements: use of 
OFA in RTX hypersensitivity is a recognised indication 
[20]. Whether OFA offers therapeutic superiority to RTX 
is unclear. Much of the lymphoma literature suggests no 
benefit [21]. A randomised controlled trial investigating low-
dose OFA versus RTX in the treatment of steroid-dependent 
NS pre-transplant, admittedly quite a different disease entity, 
was terminated early due to futility [22].
The first case series describing the use of OFA in five 
patients with SRNS, one of whom had recurrence post-
transplant [23], demonstrated remission of recurrent dis-
ease. Following the publication of that report and awareness 
amongst paediatric nephrologists, OFA has been reported 
with variable efficacy in several case reports and a small case 
series [24]. We summarise what we believe to be the known 
UK usage of OFA in paediatric kidney transplant patients, 
with additional reporting of two adult patients in our local 
unit, all of whom developed recurrent FSGS post-kidney 
transplantation.
Methods
All 13 UK paediatric nephrology centres were asked to 
inform the authors if they had used, or were aware of the use 
of, OFA for post-transplant recurrence through an electronic 
request via the British Association of Pediatric Nephrology 
(BAPN) in 2018, with additional informal communications 
with each centre by the lead author. For each case identified, 
data was collected retrospectively on disease course pre-
transplant including any identified genetic mutation, initial 
steroid sensitivity, time to CKD 5, time on dialysis and other 
immunosuppressive therapies used. Post-transplant data was 
collected either retrospectively or prospectively and included 
baseline immunosuppression, time to disease recurrence, 
whether dialysis was required, use and intensity of PLEX, 
indication, timing and dose details of OFA, and longitudinal 
measurements of serum creatinine, serum albumin, urinary 
protein/creatinine ratio and estimated glomerular filtration 
rate (eGFR, estimated using the bedside Schwarz equation). 
Data was collected for up to 2 years post-transplant or until 
another intervention after OFA occurred.
Complete urinary remission was defined as improvement 
in proteinuria to a UPCR of < 20 mg/mmol creatinine. Partial 
urinary remission was defined as improvement in proteinu-
ria to non-nephrotic range, i.e. < 200 mg/mmol creatinine. 
Normalisation of graft function was defined as an increase in 
estimated GFR from < 90 to ≥ 90 ml/min/1.73  m2. Improve-
ment of graft function was defined as an increase in eGFR 
of ≥ 10 ml/min/1.73  m2 after drug administration.
Results
The authors were personally involved with treatment of three 
patients in two UK centres at the time of the BAPN request 
in 2018. Although no additional patients were identified fol-
lowing that request or by direct communication with centres, 
three further patients were discussed with the authors, and 
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subsequently received OFA (two adult within our own unit 
and one further paediatric case in another centre). A further 
case in our own centre also received OFA following the sur-
vey. No additional paediatric cases have received OFA to 
our knowledge. Thus, seven patients from three paediatric 
centres and one adult centre are included.
In the first UK paediatric case (case 5 below), OFA was 
administered as the patient had prior hypersensitivity to 
RTX. In two cases, OFA was used after RTX administration 
post-transplant with ongoing evidence of disease recurrence. 
Two cases had previously received RTX when pre-dialysis 
without effect, so OFA was used in preference post-trans-
plant. In the other two cases, OFA was used as the initial 
monoclonal agent after detailed discussion with the family 
regarding the unknown efficacy for this indication but sug-
gestion (at the time) of clinical superiority over RTX.
The dose of OFA administered for all but case 5 was 
300 mg/1.73  m2 as an initial dose, followed by five weekly 
doses of 2000/1.73  m2 over a total of 6 weeks, unless clini-
cal circumstances led to delayed administration. The dosing 
schedule used is provided in Supplementary Appendix 1.
Notable case details are summarised in Table 1, includ-
ing initial disease course, potentially relevant transplantation 
data, details on recurrence and therapies, and biochemical 
parameters. Figure 1 summarises individual patient treat-
ments with longitudinal changes in eGFR and proteinuria. 
Each case is briefly summarised below.
Complete urinary remission occurred in three cases, all 
paediatric. Partial urinary remission to non-nephrotic range 
proteinuria occurred in one adult case, but was brief and 
rapidly reverted to nephrotic range. No urinary response 
was seen in two cases, one adult and one paediatric. One 
case had nephrotic range proteinuria with complete urinary 
remission during PLEX; this was maintained following OFA 
and rapid cessation of PLEX. Graft function normalised in 
one paediatric case following OFA. Two cases had normal 
graft function at the time of administration but ongoing 
nephrotic range proteinuria. Two cases (one paediatric, one 
adult) demonstrated improvement in graft function after 
OFA administration, but did not achieve a normal eGFR. 
No benefit was seen on graft function in two patients (one 
paediatric, one adult).
Case 1
A 7-year-old African boy received a deceased donor (DD) 
kidney transplant, 5 years after diagnosis. Pre-dialysis, RTX 
administration had not been beneficial. Disease recurrence 
was immediate, with nephrotic range proteinuria and graft 
dysfunction necessitating haemodialysis 1 day post-oper-
atively. PLEX was commenced on day 4, delivering five 
exchanges in the first week, then thrice weekly for 1 week, 
with a reducing frequency thereafter. OFA was commenced 
on day 31 post-transplant. The initial infusion was associated 
with itch, which resolved when reducing the rate of infu-
sion. Subsequent doses were uncomplicated. Kidney func-
tion improved and proteinuria declined from 4 and 6 weeks 
post-transplant, respectively.
An episode of possible rejection 2 months post-transplant 
was treated with 3 days of intravenous methylprednisolone; 
subsequent biopsy confirmed FSGS recurrence with no 
evidence of acute rejection. PLEX was discontinued after 
3 months of treatment due to loss of central venous access. 
Complete urinary remission was achieved 8 months post-
transplant and is negligible 3 years post-transplant. Graft 
function was 80–90 ml/min/1.73  m2 up to 18 months post-
transplant, but has deteriorated recently in association with 
antibody-mediated rejection.
Case 2
An 11-year-old Caucasian female received a DD kidney 
transplant, with dilatation of the proximal donor ureter. 
Delayed graft function required reinstatement of perito-
neal dialysis from day 1. Immediate nephrotic proteinuria 
suggested recurrence, so PLEX was commenced day 3 
post-transplant, three exchanges weekly for 3 weeks then 
reducing in frequency. Recurrent FSGS was confirmed his-
tologically 2 weeks post-transplant, with the administration 
of RTX 750 mg/m2 twice 1 week apart at that time. Three 
months post-transplant, nephrotic range proteinuria persisted 
so OFA was administered. B Cells were not checked prior to 
administration, so it is unknown whether early reconstitution 
had occurred. An acute kidney injury following the first dose 
was due to ureteric ischaemia, managed with re-insertion 
of ureteric stent. This delayed subsequent dosing with OFA 
by 2 weeks. No other doses were associated with adverse 
events. Proteinuria became non-nephrotic 6 months post-
transplant and demonstrated complete remission 6 months 
after OFA was completed. PLEX was discontinued 9 months 
post-transplant. She currently has normal kidney function 
(eGFR 91  ml/min/1.73  m2) and negligible proteinuria 
3 years post-transplant.
Case 3
A 23-year-old Caucasian male received a living related 
donor (LRD) transplant, with immediate graft function. 
Nephrotic range proteinuria developed on day 2 with a 
reduction in the rate of decline of serum creatinine. Alter-
nate day PLEX improved proteinuria (although still within 
nephrotic range) and kidney function—this improvement 
was not maintained when exchange frequency was reduced. 
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Table 1  Case details summarising clinical characteristics, transplant details, disease recurrence and treatments administered
Aza azathioprine, CyA ciclosporin, CYP cyclophosphamide, DBD donation after brain death, DCD donation after cardiac death, DD deceased 
donor, eGFR estimated glomerular filtration rate, FSGS focal segmental glomerulosclerosis, HLA human leukocyte antigen, IVMP intravenous 
methylprednisolone, L(R)D living (related) donor, NA not available, PLEX plasma exchange, RTX rituximab, Tac tacrolimus, TWIST basilixi-
mab, tacrolimus, mycophenolate mofetil and prednisolone, UPUC urine protein/creatinine ratio
* Genetic analyses identified autosomal recessive heterozygous mutation in PTPRO not felt to be pathogenic
 + Urinary albumin/creatinine ratio reported for case 6
Case 1 2 3 4 5 6 7
Recurrence risk
  FSGS Yes Yes Yes Yes Yes Yes Yes
  Male Yes No Yes Yes No Yes Yes
  Age at presentation (years) 1.5 6 18 43 2 2 2
  Genetic mutation None Unlikely* None Not tested None None None
  Early pre-transplant steroid sensitivity Yes Yes No Yes Yes Yes No
  No immunosuppression response None CyA None CyA CyA, Tac, RTX, CYP None None
Transplant (Tx) details
  Age at transplantation (years, months) 7y 4 m 11y 11 m 23 52 14y 4 m 6y 2 m 4y 6 m
  DD vs. LD DBD DBD L(R)D DCD LD L(R)D L(R)D
  Warm ischaemic time (min) 53 42 32 15 47 39 57
  Cold ischaemic time 25 h 6 min 22 h 5 m 2 h 57 min 10 h 2 min 9 h 14 min 85 min 4 h 57 min
  HLA mismatch 111 111 100 010 110 011 111
  Immunosuppression TWIST TWIST TWIST TWIST Tac/Pred/Aza TWIST TWIST
Recurrence details
  Onset of UPUC > 200 mg/mmol (days 
post-transplant)
0 0 2 7 0 0 0
  Histological confirmation of recurrence Yes Yes Yes Yes No No Yes
  Dialysis requirement post-transplant Yes Yes No No Yes Once Yes
  Duration of dialysis requirement (days) 42 17 – – 4 1 27
Treatment details
  Time 1st PLEX (days post-Tx) 3 5 19 63 3 1 1
  UPUC pre-ofatumumab 3235 2907 132 162 16 2155+ 10,905
  eGFR pre-ofatumumab 34 99 48 28 91 93 6
  Time 1st ofatumumab (days post-Tx) 31 104 143 106 27 138 1
  Time to complete 6 doses 7 weeks 9 weeks 7 weeks 7 weeks 2 doses only 7 weeks 7 weeks
  Time on PLEX (months) 3 9 10 9 1 6 5




  Time post-Tx to UPUC < 200 (days) 58 204 17 14 20 NA 132
  Time post-Tx to complete remission 
UPUC < 20 mg/mmol (days)
128 321 NA NA 26 328 165
  UPUC 3 months post-OFA (mg/mmol 
creat)
55 123 363 201 12 2661+ 225
  eGFR 3 months-post OFA (ml/
min/1.73  m2)
76 126 30 29 92 76 52
  UPUC 6 months post-OFA (mg/mmol 
creat)
 < 3  < 3 366 310 6 25+  < 3
  eGFR 6 months post-OFA (ml/
min/1.73  m2)
68 130 33 38 114 72 39
  UPUC 12 months post-OFA (mg/mmol 
creat)
 < 3 14 197 263 AWAITED NA  < 3
  eGFR 12 months post-OFA (ml/
min/1.73  m2)
90 113 45 44 103 NA 45
  6 month serum albumin (g/dl) 35 30 37 31 38 24 43
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Biopsy demonstrated widespread foot process effacement 
but normal light microscopy appearance. Frequency of 
PLEX was maintained at thrice weekly. OFA was consid-
ered, as RTX was ineffective pre-dialysis, and commenced 
5 months after transplant. He developed a mild rash during 
the first infusion but no other adverse effects were noted 
during the remaining infusions. A brief improvement in pro-
teinuria to 97 mg/mmol 3 weeks after completion of OFA 
was not maintained, with rapid recurrence of nephrotic range 
proteinuria. No improvement in graft function was noted, 
although this stabilised at 50–60 ml/min/1.73  m2.
Case 4
A 53-year-old Caucasian male received a DD kidney trans-
plant. Graft function was immediate, but did not improve 
as expected, and non-nephrotic range proteinuria persisted, 
prompting a trial of PLEX. Non-nephrotic range proteinu-
ria (82–173 mg/mmol) continued, as did graft impairment 
(eGFR 26–30 ml/min/1.73  m2), so additional immunother-
apy was considered. Given the absence of response to RTX 
pre-transplant, OFA was administered. No adverse effects 
were noted. There was no urinary response; proteinuria 
deteriorated and entered the nephrotic range. Graft function 
improved slowly over time, from 20 to 30 ml/min/1.73  m2 at 
the time of initial OFA administration to 40–50 ml/min/1.73 
 m2 12 months later.
Case 5
A 14-year-old Caucasian female received an altruistic liv-
ing unrelated transplant. Nephrotic range proteinuria was 
evident by day 2 post-transplant, with PLEX commenced 
on day 3. Graft dysfunction continued with an early biopsy 
demonstrating acute tubular injury. Hemodialysis was 
required between day 7 and day 11 post-transplant. Five 
sessions of PLEX over 2 weeks were followed by four ses-
sions over 3 weeks. The patient had previously experienced a 
serum-sickness-like reaction to RTX, so received two doses 
of OFA 700 mg (approximately 750 mg/1.73  m2) on days 25 
and 32 post-transplant. Graft function and proteinuria had 
normalised prior to OFA administration. PLEX was discon-
tinued after the first dose of OFA. The patient maintained 
complete urinary remission and normal graft function for 












Case 3 - Adult
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Fig. 1  Longitudinal timeline for all patients demonstrating change 
in proteinuria and estimated GFR, relating to administration of plas-
mapheresis, rituximab (where relevant) and ofatumumab. The light 





was associated with medication non-concordance, with no 
associated proteinuria.
Case 6
A 6-year-old Caucasian male received a LRD kidney trans-
plant. Graft function was evident at 24 h with immediate 
nephrotic range proteinuria, leading to treatment with RTX 
and PLEX, initially 10 doses in 2 weeks and subsequently 
3 doses each week. An episode of possible rejection was 
treated with IV methylprednisolone. Proteinuria remained 
in the nephrotic range, prompting administration of OFA 
4 months following transplantation, with no adverse effects 
observed during infusions. No change in proteinuria or graft 
function was seen in the 3 months following OFA adminis-
tration. Low-density lipoprotein apheresis was subsequently 
commenced 8 months post-transplant, with complete remis-
sion of proteinuria and maintained graft function.
Case 7
A 4-year-old Caucasian male received a LRD kidney trans-
plant. Graft function was immediate, with nephrotic-range 
proteinuria evident at 12 h post-transplant. PLEX was com-
menced days 1 and 2 post-transplant, then 8 sessions over 
2 weeks, weaning to 3 sessions/week for 3 weeks, 2 sessions/
week for 4 weeks, weekly for 4 weeks, then finally every 
2 weeks for 4 sessions. OFA was commenced day 1 post-
transplant; no adverse reactions were noted. FSGS recur-
rence was confirmed histologically 6 weeks post-transplant. 
No response was seen initially—nephrotic range proteinu-
ria persisted and eGFR was 40 ml/min/1.73  m2 at 3 months 
post-transplant. A suspected episode of rejection was treated 
with pulsed IV methylprednisolone—this led to dramatic 
improvement in both proteinuria and graft function. His-
tology demonstrated no rejection; only evidence of FSGS 
recurrence. Renewed steroid sensitivity was suspected, so 
oral steroids were continued on a slowly weaning course. At 
12 months post-transplant, graft function improved to 60 ml/
min/1.73  m2 and complete urinary remission was achieved.
Discussion
We describe seven patients, five paediatric and two adult, 
who received OFA as part of their therapeutic strategy 
for recurrent FSGS post-kidney transplant, with vari-
able efficacy. This case series represents one of the larger 
series in the literature, provides medium-term follow-up 
to 2 years post-transplantation, and reports both success-
ful and unsuccessful outcomes. This is the first report of 
OFA in adult FSGS recurrence. No patients received OFA 
in isolation—all had other immunomodulatory therapies 
ongoing, including plasmapheresis.
Reduction in proteinuria was evident in all paediatric 
patients, with four/five demonstrating complete urinary 
remission between 6 and 9 months post-transplant, and all 
in complete urinary remission by 12 months. Introduction 
of steroids in one patient, and usage of lipid apheresis in 
another, was closely associated with urinary remission in 
two cases, so causation by OFA cannot be assumed. A 
maintained response was not seen in either of the adult 
patients receiving OFA.
Improvement in graft function was only seen in 2/7 
patients. Two paediatric patients had good graft function 
prior to OFA administration. Graft function improved 
to a normal eGFR in one of the paediatric patients and 
improved over time (though still impaired) in one adult 
and one paediatric patient. No benefit on graft function 
was seen for two patients.
Pediatric FSGS is associated with a much greater risk of 
disease recurrence than FSGS occurring in adult patients, 
with young age of onset a key risk factor [18]. In one 
series, 86% of paediatric patients had disease recurrence, 
compared to 35% of adult patients. However, younger 
patients may have a different disease entity or responsive-
ness compared to older patients [18, 25]. Adult remission 
rates from recurrence occur in ~ 50% of patients [5]. Deter-
mining the remission rate in children is more difficult, due 
to publication bias, lack of large case series and relative 
rarity of the diagnosis. No literature exists on OFA in adult 
FSGS, so it is unknown whether the absence of response 
seen in our two patients is as expected. The modest but 
evident improvement in most paediatric patients in this 
series, compared to adult patients, again suggests that pae-
diatric FSGS may have a more modifiable disease course.
Six of the seven patients received a short course of 
prednisolone immediately post-transplantation. Although 
there is a recognised increased risk of disease recurrence 
associated with steroid minimisation regimens for some 
immunologically mediated renal conditions, there is no 
definitive support that this is the case for FSGS. Two adult 
cohorts totalling 148 patients and one paediatric cohort of 
25 patients did not demonstrate increased recurrence risk 
with short steroid regimens [26–28].
There are several limitations to this paper. Most impor-
tantly, all patients also received concomitant PLEX, which 
is a major confounding factor and may also account for 
improvement in proteinuria and graft function. Although 
this confounding effect of ongoing PLEX cannot be 
excluded, in two patients with clinical response, one had 
a rapid cessation of plasmapheresis following OFA due to 
technical issues (case 1), and the second had received a 
lengthy trial of plasmapheresis with no clear benefit prior 
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to OFA administration (case 2). We believe OFA directly 
benefited these patients.
Other limitations include the significant case heterogene-
ity, particularly with other immunosuppression. One patient 
received LDL apheresis, and a second was re-commenced 
on corticosteroids after OFA administration. One patient 
had normalisation of graft function and proteinuria prior to 
OFA administration so determining benefit is impossible. 
Two patients received RTX within 6 months prior to OFA 
administration—B-cell data is unavailable so it is unknown 
whether either patient had reconstituted by the time of OFA 
infusion. It is plausible that ongoing improvement in one of 
these two patients could be attributable to RTX, although 
the second patient had no change in clinical course until 
LDL apheresis was introduced. One patient demonstrated 
marked improvement after the administration of high-dose 
corticosteroids, having previously been steroid resistant—
again, clinical improvement may not be attributable to the 
OFA. The total number of patients in this series remains 
small, across several centres—there may have been practice 
variation in other aspects of transplant care that could also 
be confounding. The indications for OFA were also varied—
previous RTX hypersensitivity, previous failure of RTX pre- 
or post-transplant, and latterly, used in preference to RTX 
due to previous perceived patient improvement.
OFA is a fully humanised anti-CD20 monoclonal anti-
body, initially used in patients with chronic lymphocytic leu-
kaemia, and licensed for patients with a recognised sensitiv-
ity/anaphylaxis to RTX administration. OFA has since been 
reported in a variety of different conditions, most commonly 
in patients unable to tolerate RTX, including anti-neutrophil 
cytoplasmic antibody-associated vasculitis, IgA nephropathy 
and lupus nephritis [29–31]. Similar to RTX, the first usage 
in NS was in a patient with both resistant NS and leukaemia 
[32]. Several reports now exist of OFA usage in both steroid-
sensitive and steroid-resistant NS, where either there was 
absence of response to RTX or patients had hypersensitivity 
reactions [20, 23, 33]. An open-label randomised controlled 
trial comparing RTX and OFA in paediatric steroid-depend-
ent NS ended early due to futility, although notably used a 
far lower dose of OFA than previous reports [22]. Disease 
remission of SRNS has occurred in a significant majority 
of reported patients [23], although this may be subject to 
publication bias. The same case series also included a desen-
sitisation protocol, as four of that centre’s five patients dem-
onstrated hypersensitivity reactions [23].
In our series, no major infusion reactions were noted in 
any patient. One patient had itch during the first infusion, a 
second patient developed urticaria which rapidly settled—
neither required any additional intervention other than symp-
tomatic treatment and tolerated further infusions with no 
complication. All patients completed the intended course 
of OFA (in case 5, OFA was used at lower dose). No major 
infective episodes were identified during the initial adminis-
tration or in the 2 years subsequently. One patient developed 
transplant ureter ischaemia and subsequent necrosis, attrib-
uted to pre-existing anatomical abnormalities noted at the 
time of anastomosis—although a correlation with OFA can-
not be excluded. The overall adverse effect profile of OFA 
appears acceptable in both the chronic lymphocytic leukae-
mia population [34] and in children with NS [35] with infu-
sion reactions and infection being most commonly reported.
Usage of OFA for post-transplant recurrence has now 
been reported in several case reports and small case series 
[24, 36–38]. Colucci et al. reported two patients demonstrat-
ing a complete and partial remission [37]; Solomon et al., 
a patient with partial remission [36]. All three patients had 
initially received RTX with no maintained improvement. 
Kienzl-Wagner reported pre- and post-transplant treatment 
with OFA and PLEX in a patient receiving their second 
graft, with partial remission achieved [38]. Bernard et al. 
reported one patient with partial remission following OFA in 
a patient receiving their second renal graft, i.e. particularly 
high risk for disease recurrence [39]. In the last two patients, 
disease recurrence was associated with B-cell reconstitu-
tion and repeated OFA dosing maintained a partial remis-
sion. The same group reported the outcome of six patients 
(including the patient above), three achieving partial remis-
sion and three having no response [24]. Two different dose 
strategies were used, patients had a median age of 16 years, 
and administration of OFA was performed between 1 month 
and 3 years post-transplant, so a significant patient hetero-
geneity was evident. These papers support our findings that 
OFA may have a role where there has been a lack of efficacy 
from RTX, but that it does not benefit all patients, and those 
benefits may be modest.
The mechanism of action of OFA in FSGS recurrence 
requires further elucidation. Whether B-cell depletion is 
responsible for disease remission is complicated by dem-
onstration of direct binding of RTX to podocytes [17], 
although the validity of this has been questioned and an 
effect on Interleukin-4 proposed as an alternative mecha-
nism [40]. However, RTX has a demonstrable improvement 
on proteinuria in animal models of chemical (adriamycin) 
induced nephropathy [41], i.e. unrelated to immunological 
aetiologies. OFA binds to a different CD20 epitope with 
greater avidity and induces more cell-dependent cytotoxicity 
than RTX [42] with demonstrably better outcomes compared 
to RTX in murine models of lymphoma [43]. There has been 
no work to date examining OFA binding sites on the podo-
cyte. Greater avidity, alternative binding or a differential 
effect on B-cell function may all contribute to explaining 
OFA response in patients with RTX resistance.
Other novel anti-CD20 monoclonal agents, including 
obinutuzumab and ocrelizumab, have been licensed for 
other indications in adult patients. Whether these will have 
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similar safety and efficacy profiles in children is unknown, 
and molecular differences preclude assuming the same 
responses, although obinutuzumab may be predicted to have 
similar efficacy. OFA was withdrawn commercially from the 
European Union in 2019, although it is still available in the 
USA and on an individual compassionate basis by appli-
cation—the authors have used this route successfully for 
UK patients. A subcutaneous preparation of OFA for adult 
patients with multiple sclerosis has recently been approved.
Conclusion
We report a small case series of seven patients receiving 
therapeutic OFA for recurrent FSGS post-kidney transplan-
tation. Four of five paediatric cases demonstrated improve-
ment, with either complete or partial remission. Neither 
adult patient demonstrated an objective maintained response. 
All patients received concomitant plasmapheresis, which is 
a crucial limitation and prevents attribution of response to 
OFA. Recognised adverse effects from OFA were mini-
mal and did not prevent further dose administrations. The 
mechanisms of action of B-cell depletion in mitigating 
FSGS recurrence remain unclear. Whether OFA offers any 
superiority to RTX as an adjunct treatment is unknown, but 
it appears a safe alternative.
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